Elbasvir-Grazoprevir Zepatier
Glecaprevir-Pibrentasvir Mavyret
Ledipasvir-Sofosbuvir Harvoni
Ribavirin Copegus, Rebetol, Ribasphere
Sofosbuvir SovaldiAll Clinical Trials
Filter by Category
- All Clinical Trials
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Resistance/Virological Failure
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
- Pharmacology
- Adverse Effects
- Adverse Effects
Official Title Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection
Phase Phase III
ClinicalTrials.gov NCT02607735
Treatments
Sofosbuvir-Velpatasvir-Voxilaprevir
Sofosbuvir-Velpatasvir-Voxilaprevir
Tradename:VoseviOther Names:SOF-VEL-VOXClass:FDA-ApprovedFunding
IndustryGilead Sciences
References
- Bourlière M, Gordon SC, Flamm SL, et al. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. N Engl J Med. 2017;376:2134-46.
Official Title Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials
Phase Phase III
ClinicalTrials.gov NCT02607800
Treatments
Sofosbuvir-Velpatasvir
, 
Sofosbuvir-Velpatasvir
Tradename:EpclusaOther Names:SOF-VELClass:FDA-ApprovedSofosbuvir-Velpatasvir-Voxilaprevir
Sofosbuvir-Velpatasvir-Voxilaprevir
Tradename:VoseviOther Names:SOF-VEL-VOXClass:FDA-ApprovedFunding
IndustryGilead Sciences
References
- Jacobson IM, Lawitz E, Gane EJ, et al. Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. Gastroenterology. 2017;153:113-22.
Official Title Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.
Phase Phase III
ClinicalTrials.gov NCT02639338
Treatments
Sofosbuvir-Velpatasvir
, Sofosbuvir-Velpatasvir
Tradename:EpclusaOther Names:SOF-VELClass:FDA-ApprovedSofosbuvir-Velpatasvir-Voxilaprevir
Sofosbuvir-Velpatasvir-Voxilaprevir
Tradename:VoseviOther Names:SOF-VEL-VOXClass:FDA-ApprovedFunding
IndustryGilead Sciences
References
- Jacobson IM, Lawitz E, Gane EJ, et al. Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. Gastroenterology. 2017;153:113-22.
Official Title Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection
Phase Phase III
ClinicalTrials.gov NCT02639247
Treatments
Sofosbuvir-Velpatasvir-Voxilaprevir
Sofosbuvir-Velpatasvir-Voxilaprevir
Tradename:VoseviOther Names:SOF-VEL-VOXClass:FDA-ApprovedFunding
IndustryGilead Sciences
References
- Bourlière M, Gordon SC, Flamm SL, et al. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. N Engl J Med. 2017;376:2134-46.
Official Title A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY)
Phase Phase IIB
ClinicalTrials.gov NCT02745535
Treatments
Sofosbuvir-Velpatasvir-Voxilaprevir
Sofosbuvir-Velpatasvir-Voxilaprevir
Tradename:VoseviOther Names:SOF-VEL-VOXClass:FDA-ApprovedFunding
IndustryGilead Sciences
Non-IndustryIntramural Research Pro- gram of the NIH, Clinical Center
References
- Wilson E, Covert E, Hoffmann J, et al. A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY). J Hepatol. 2019;71:498-504.
Official Title Sofosbuvir/Velpatasvir/Voxilaprevir for Previous Treatment Failures With Glecaprevir/Pibrentasvir in Chronic Hepatitis C Infection
Treatments
Sofosbuvir-Velpatasvir-Voxilaprevir
Sofosbuvir-Velpatasvir-Voxilaprevir
Tradename:VoseviOther Names:SOF-VEL-VOXClass:FDA-ApprovedReferences
- Pearlman B, Perrys M, Hinds A. Sofosbuvir/Velpatasvir/Voxilaprevir for Previous Treatment Failures With Glecaprevir/Pibrentasvir in Chronic Hepatitis C Infection. Am J Gastroenterol. 2019;114:1550-2.
Sofosbuvir-Velpatasvir-Voxilaprevir Slide Deck
Clinical Trial Image Decks
POLARIS-1 - June 30, 2022
POLARIS-2 - June 30, 2022
POLARIS-3 - June 30, 2022
POLARIS-4 - June 30, 2022
RESOLVE - June 30, 2022
SOF-VEL-VOX in G/P Failure - September 17, 2023